Lipid nanoparticles as an emerging platform for cannabinoid delivery: physicochemical optimization and biocompatibility

This work aims at developing and optimizing a valuable oral delivery carrier for the cannabinoid derivative CB13, which presents a high therapeutic potential in chronic pain states that respond poorly to conventional analgesics, but also shows highly unfavorable physicochemical properties. CB13-load...

Full description

Saved in:
Bibliographic Details
Published inDrug development and industrial pharmacy Vol. 42; no. 2; pp. 190 - 198
Main Authors Durán-Lobato, M., Martín-Banderas, L., Lopes, R., Gonçalves, L. M. D., Fernández-Arévalo, M., Almeida, A. J.
Format Journal Article
LanguageEnglish
Published England Taylor & Francis 01.02.2016
Subjects
Administration, Oral
Animals
Cannabinoids - administration & dosage
Cannabinoids - chemistry
Chemistry, Pharmaceutical - methods
Drug Carriers - chemistry
Drug Compounding - methods
Drug Delivery Systems
Drug Stability
HEK293 Cells
Humans
Lipid carriers
Lipids - chemistry
Mice
nanoparticle formulation
Nanoparticles
Naphthalenes - administration & dosage
Naphthalenes - chemistry
neuropathic pain
NIH 3T3 Cells
oral delivery
poor soluble drugs
neuropathic pain
poor soluble drugs
Lipid carriers
nanoparticle formulation
oral delivery
Online AccessGet full text

Cover

More Information
Summary:This work aims at developing and optimizing a valuable oral delivery carrier for the cannabinoid derivative CB13, which presents a high therapeutic potential in chronic pain states that respond poorly to conventional analgesics, but also shows highly unfavorable physicochemical properties. CB13-loaded lipid nanoparticles (LNP) formulations were developed through solvent-emulsion evaporation and optimized in terms of physicochemical properties, long-term stability, integrity under gastric simulated conditions and in vitro interaction with NIH 3T3, HEK 293T and Caco-2 cells. An optimized formulation of LNP containing CB13 was obtained from a wide range of conditions assayed and analyzed. The selection of the lipid core, production conditions and the inclusion of lecithin proved to be key factors for the final properties of encapsulation, integrity and performance of the carriers. The LNP formulation proposed proved to be a promising carrier for the oral delivery of CB13, a cannabinoid with high therapeutic potential in chronic pain states that currently lack a valid oral treatment.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0363-9045
1520-5762
DOI:10.3109/03639045.2015.1038274